Targeted therapies are increasingly being evaluated for patients with Ewing sarcoma (EWS). Optimal strategies for quantifying key signaling proteins in EWS remain unclear. We sought to quantify tumor expression of signaling pathway proteins in EWS using 3 methodologies. A total of 46 blocks of formalin-fixed paraffin-embedded tissue were obtained from 40 patients with EWS. Tumor was evaluated for the expression of proteins in the insulin-like growth factor type 1 receptor (IGF-1R), epithelial growth factor receptor (EGFR), and mTOR pathways using standard immunohistochemical analysis (IHC), automated quantitative analysis (AQUA) immunohistochemical analysis, and mass spectrometry quantification. The mean age at diagnosis was 14 years (range, 1 to 49 y). About 67.5% were male and 57.5% had localized disease. Samples displayed a wide range of expression by AQUA: mean (range) IGF-1R = 10,702 (393 to 14,424); EGFR = 2750 (672 to 9798); and phosphatase and tensin homolog (PTEN) = 2250 (251 to 6557). Mean IGF-1R expression by AQUA did not differ between standard IHC expression categories (low IHC = 11,255; medium IHC = 11,070; high IHC = 11,023; P = 0.98). Mean PTEN expression by AQUA was higher in the medium and high IHC categories (low IHC = 1229; medium IHC = 2715; high IHC = 2940; P = 0.064). Only 2 samples expressed EGFR by standard IHC. Mass spectrometry trended toward correlation with standard IHC but did not yield interpretable results in the majority of samples. This study demonstrates that the relative quantification of signaling protein expression in EWS is dependent on the methodology used. Optimization and validation of these tools are necessary before clinical application for risk stratification of patients or measurement of biomarker expression.
bone and soft tissues with a peak incidence rate in adolescence. Outcomes for patients with localized disease have improved over the past 20 years, with approximately 70% of patients disease-free 5 years from initial diagnosis. 1 In contrast, outcomes for patients with initially metastatic disease remain poor. Only 20% to 25% of these patients survive disease-free 5 years from initial diagnosis. 1, 2 Outcomes for patients with recurrent disease are also generally poor. [3] [4] [5] As a result, targeted therapies are being increasingly evaluated in these populations.
The insulin-like growth factor type 1 (IGF-1), epithelial growth factor (EGF), and mTOR pathways have been shown to play important roles in the growth of EWS. [6] [7] [8] [9] Multiple preclinical models have shown that EWS growth is inhibited by agents that interrupt these pathways by blocking IGF-1 receptor (IGF-1R) and mTOR. [10] [11] [12] Inhibition of epithelial growth factor receptor (EGFR) has been shown to be cytotoxic to EWS cells in vitro, and increased EGFR expression may be a mechanism of resistance to IGF-1R inhibition. 13, 14 In the case of IGF-1R inhibitors, only a subset of patients has a clinical response, although with significant improvements in disease burden. 15, 16 Many groups have noted the need for improved use of biomarkers to identify patient subgroups who are most likely to respond to these targeted therapies. [17] [18] [19] Furthermore, there is evidence that tumor expression of some growth signaling proteins is correlated to overall survival and thus quantified measurements of these proteins may be useful as prognostic biomarkers. 20 However, the optimal modality for quantifying expression of these proteins in the type of tumor material most commonly available for evaluation, formalin-fixed paraffin-embedded tissue, has not been determined.
Several methods are available for quantifying clinically relevant signaling pathway proteins in archival paraffinembedded tumor material: standard immunohistochemical analysis (IHC); automated quantitative analysis (AQUA) immunohistochemical analysis 21 ; and mass spectrometry quantification. 22 Although standard IHC is widely available, it is only semi-quantitative and cannot be multiplexed. AQUA IHC and mass spectrometry have the benefit of being both fully quantitative and can be tested as a multiplex assay. However, neither of the assays have been compared with IHC for use with signaling proteins in EWS.
The primary aim of the present study was to compare the performance characteristics of these techniques in tissue samples obtained from EWS patients in quantifying IGF-1R, EGFR, and mTOR signaling pathway proteins. A secondary aim was to track expression of these antigens over the disease course. The results could then be used to inform the adoption of new technologies for use in clinical trials of targeted agents for EWS and potentially other childhood cancers.
MATERIALS AND METHODS

Patients
Tissue samples were obtained by evaluating the records of 129 patients with confirmed EWS who have been previously treated at the University of California, San Francisco. From the potential pool of 129 patients, our study population was limited to those patients who underwent open diagnostic biopsies or surgical resection of their tumor and excluded patient samples obtained by needle biopsy. Patients who underwent open biopsy or resection at the time of relapse were also included. The presence of viable tumor cells readily visible microscopically was also required for inclusion. These criteria were designed to ensure sufficient tumor material for analysis. Sixty-three patients were screened based on available material. A total of 46 blocks of formalin-fixed tissue with viable tumor were available from 40 of the original 63 patients included. Thirty-four blocks of skeletal origin were decalcified using EDTA and dilute HCl (Decal Stat; Decal Chemical Corporation, Tallman, NY). Twentyeight of the 46 samples were obtained at time of initial diagnosis, 11 after initial neoadjuvant chemotherapy during primary surgical excision, and 7 from patients with relapsed disease. The remaining 23 patients were excluded because of insufficient viable tumor, typically, as a result of chemotherapy effect (n = 18). Five patients had tissue blocks that could not be located. Six of the 40 patients had samples both at the time of diagnosis and after initial therapy. Five of these patients had tissue obtained after initial neoadjuvant chemotherapy and 1 after treatment relapse. One pathologist (A.E.H) reviewed all cases to confirm the diagnosis of EWS based on histology, IHC, and/or cytogenetic/molecular data.
Study Overview
The initial study design included evaluation of protein expression of IGF-1R, phospho-IGF-1R, phospho-AKT, phosphatase and tensin homolog (PTEN), EGFR, and phospho-P70S6 kinase. These proteins were chosen because they are involved in signaling pathways of potential interest for targeted therapy for EWS, including IGF-1R, EGFR, and mTOR pathways.
All samples were evaluated by standard IHC and AQUA IHC including 6 patients with samples from both diagnosis and after treatment. Twenty-five samples were also selected for mass spectrometry analysis using tissue samples obtained from 20 patients. Each of the selected patients had their diagnostic sample tested by mass spectrometry. Five of these patients had paired samples from a second timepoint, 4 after chemotherapy, and 1 at time of relapse who were further evaluated to better understand the changes observed in these biomarkers after treatment.
Sample Preparation and Evaluation
Tissue microarrays (TMAs) were prepared for both standard and AQUA IHC. Positive and negative controls included normal liver, kidney, and tonsil tissue.
Immunohistochemical staining was performed with the Dako Autostainer (Dako, Carpinteria, CA) using DAKO LSAB+ or polymerized detection system (Envi-sion+; Dako) and diaminobenzadine as the chromogen, as noted in Supplementary Microwave citric acid epitope retrieval was used for all antibodies with the exception of EGFR. Appropriate negative (no primary antibody) and positive controls were stained in parallel with each set of tumors studied and yielded expected positive and negative staining Protein expression by standard IHC was evaluated using a 0 to 8 scale, 8 being the strongest staining using the modified Allred scoring schema. 23 Standard IHC results were also categorized as low (0 to 2), medium (3 to 5) and high (6 to 8). Samples were evaluated by a single pathologist (D.T.). Scoring was done blinded to results obtained from AQUA or mass spectrometry to prevent bias.
Double immunofluorescence staining for AQUA was performed as previously described. 24 Briefly, after deparaffinization and rehydration, TMA slides were subjected to microwave epitope retrieval in 1 mM EDTA buffer (pH 8). After rinsing several times in 10 mM Tris HCl buffer (pH 8) containing 0.154 M NaCl (TBS), endogenous peroxidase activity was blocked with 2.5% (vol/vol) H 2 O 2 in methanol for 30 minutes. Nonspecific binding of the antibodies was extinguished by a 30-minute incubation period with "Background Sniper" (BioCare Medical, Concord, CA). The TMA slide was then incubated with the tumor-specific antibody, CD99 (species noted in Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/ AIMM/A35), overnight at 41C and with each antibody noted in Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/AIMM/A35. Slides were then washed as described above and incubated with a combination of goat anti-mouse immunoglobulin G (IgG) conjugated to AF555 (A21424, 1:200; Molecular Probes, Carpinteria, CA) in goat anti-rabbit Envision+ (Dako) or goat anti-rabbit IgG conjugated to AF555 (A31630, 1:200; Molecular Probes, Carpinteria, CA) in goat anti-mouse Envision+ (Dako) for 60 minutes at room temperature in a dark humidity tray. The slides were then washed as described above and the target image was developed by a CSA reaction of Cy5-labeled tyramide (1:50; PerkinElmer, Waltham, MA). The slides were washed with 3 changes of TBS and stained with the DNA staining dye 4 0 ,6-diaminodo-2-phenylindole (DAPI) in a nonfading mounting media (ProLong Gold, Molecular Probes). The slides were allowed to dry overnight in a dark dry chamber and the edges were sealed.
The AQUA system (HistoRx, New Haven, CT) was used for the automated image acquisition and analysis.
Briefly, images of each TMA core were captured by an Olympus BX51 microscope at 3 different extinction/ emission wavelengths. Within each TMA spot, the area of tumor was distinguished from stromal and necrotic areas by creating a tumor-specific mask from the anti-CD99 protein, which was visualized from Alexafluor 555 signal. The DAPI image was then used to differentiate between the cytoplasmic and nuclear staining within the tumor mask. Finally, the fluorescence pixel intensity of the protein/antibody complex was obtained from the Cy5 signal and was reported as mean pixel intensity. Expression by AQUA was therefore measured as a continuous variable in arbitrary units.
For mass spectrometry analysis, 10 mm unstained sections of each sample were prepared on proprietary Director slides (OncoPlex Diagnostics, Rockville, MDformerly Expression Pathology Inc.). Liquid tissue lysates were prepared from these slides according to the manufacturer's recommendations (OncoPlex Diagnostics). 22 Total protein content for each liquid tissue lysate was measured using a Micro BCA assay (Thermo Fisher Scientific Inc., Rockford, IL). Endogenous EGFR was quantitated using selected reaction monitoring (SRM)-MS by targeting the peptide IPLENLQIIR, which spans residues 98 to 108 of the EGFR extracellular domain. Likewise, IGR-1R was quantitated by targeting the peptide GNLLINIR, which spans residues 358 to 365 of the protein's extracellular domain. A known amount of synthetic isotopically labeled internal standard (5 fmol) for each peptide (IPLEN[13C15N]LQIIR and GNL [13C15N]LINIR) was added to the samples. The sample (1 mg total) was analyzed using a nanoAcquityLC system (Waters, Milford, MA) coupled directly online with a TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific, San Jose, CA). The SRM-MS assays were acquired using the following mass spectrometer conditions: Q1(FWHM); 0.2, Q2(FWHM): 0.7, dwell time; 10 ms. The precursor and product ions monitored for SRM-MS analysis of EGFR and IGF-1R have been reported previously. 22 Each sample was analyzed in triplicate. PTEN was not included in the mass spectroscopy panel for technical reasons. The area under the curve for the endogenous and isotopically labeled standard peptide was used to calculate the absolute abundance of EGFR and IGF-1R in each sample. The concentration of endogenous SPARC peptide was calculated using the following formula:
Statistical Methods
Correlation coefficients were calculated by linear regression. One-sided analysis of variance was used to compare the mean AQUA expression for each analyte between categories of expression by IHC using a single sample from each patient at the earliest timepoint in their disease. Two-sided unpaired t tests were used to compare means between groups at initial diagnosis and after initiation of chemotherapy. All statistical analyses were performed using STATA, version 11.
RESULTS
Patient Characteristics
Samples were available from a total of 40 patients whose characteristics can be seen in Table 1 . The mean age of patients was 14 years (range, 1 to 49 y) at the time of diagnosis. About 67.5% were male and 57.5% had localized disease. Overall survival for this cohort was 72.5% with a median follow-up time of 51 months.
Protein Expression by Standard IHC, AQUA IHC, and Mass Spectrometry
AQUA and standard IHC were attempted for EGFR, IGF-1R, phospho-AKT, phospho-IGF-1R, phospho-70S6k, and PTEN. Because of technical issues, results were only available for IGF-1R, EGFR, and PTEN, an inhibitor of the Pi3K/AKT/mTOR pathway. One sample per patient was analyzed, with the sample from initial diagnosis included in the primary analysis if multiple samples were available in a given patient. Overall expression results can be seen in Figure 1 . Mass spectrometry yielded expression results in 7 of 25 samples (25%) for IGF-1R and 8 of 25 samples (32%) for EGFR. PTEN expression was not available using this methodology. To account for the possible loss of protein from decalcification, we compared samples from both skeletal and nonskeletal origin and saw similar ranges for all proteins and methodologies.
AQUA IHC Compared With Standard IHC
Mean IGF-1R expression by AQUA did not differ significantly between standard IHC expression categories (mean IGF-1R expression by AQUA for low IHC = 11,255; medium IHC = 11,070; high IHC = 11,023; P = 0.98; Fig. 2A ). Mean PTEN expression by AQUA was higher in the medium and high IHC categories (mean PTEN expression by AQUA for low IHC = 1229; medium IHC = 2715; high IHC = 2940; P = 0.064; Fig. 2B ). Only 2 samples expressed EGFR by standard IHC (Fig. 2C ). These samples qualitatively had higher AQUA expression levels, but there were too few samples for a reliable determination of statistical significance.
Mass Spectrometry Compared With Standard IHC and AQUA IHC
Qualitatively, there appeared to be a trend toward higher mass spectrometry values correlating with higher standard IHC (Fig. 3A) and AQUA (Fig. 3B) expression, but there were too few samples with available mass spectrometry data to merit formal statistical analysis.
Protein Expression Levels Over Time
To better understand the changes in these biomarkers after treatment, we compared 6 posttreatment samples, 5 after chemotherapy, and 1 at time of relapse, with those obtained from the same patient at initial diagnosis by AQUA ( Fig. 4) . Intrapatient variability in expression as detected by AQUA was minimal as levels after initiation of therapy were similar to those measured before treatment. There was also no difference observed in mean expression by AQUA for all diagnostic samples compared with those obtained after initiation of 
DISCUSSION
In this study, we demonstrated the feasibility of quantifying protein expression of IGF-1R, EGFR, and PTEN in paraffin-embedded tumor samples from patients with EWS. AQUA IHC showed that tumors express these proteins across a wide range. Furthermore, although IGF-1R expression by AQUA was similar across a range of standard IHC expression categories, increased expression of PTEN and EGFR by AQUA showed a trend toward increased standard IHC expression.
In this initial descriptive study, it was not possible to determine if one approach should be favored over the other approaches as a tool for quantifying these pathways in EWS. Ultimately, a reliable quantitative method could be used for establishing relative expression values that are clinically significant. It is not known whether there are critical threshold levels of expression of these signaling proteins that correlate with clinical behavior of EWS. Our work lays the groundwork for future studies that seek to determine the clinical impact of expression of these proteins, particularly within the context of clinical trials of targeted therapies.
Importantly, there is not a gold standard to which the results of each assay could be compared. Therefore, other performance characteristics must drive selection of a particular assay for use in future testing. For example, the low success rate for mass spectrometry in this histology suggests that this platform may not be optimal for future study. AQUA may be preferred over standard IHC as a more objective and more quantitative method, although it is important to note that correlation between these 2 approaches was poor for IGF-1R. These 2 methods are also capable of determining nuclear versus cytoplasmic protein expression levels and could be evaluated in future studies. 25 Similar to AQUA, mass spectrometry also demonstrated a wide range of protein expression of IGF-1R and EGFR across samples. Higher mass spectrometric values appeared to correspond to high levels of expression on standard IHC. Unfortunately, this technique was not able to determine protein expression for a majority of the tumor samples tested. However, the mass spectrometry technique does define a lower limit of sensitivity and it may be that the low success rate also represents clinically insignificant levels of detection in these samples. Given previous success with this technique in other tumor types using frozen tissue samples, 26, 27 it is possible that the formalin fixation and, in a subset of cases, decalcification, may have interfered with this approach. Although the protein expression levels in our study using tissue from skeletal and extraskeletal sources appeared similar, more samples would be needed to confirm this finding.
Interestingly, we observed stable expression levels of IGF-1R, EGFR, and PTEN when evaluated at multiple time points in therapy for an individual patient. This result is noteworthy as many centers are utilizing core needle biopsies or fine-needle aspiration to render an initial diagnosis of EWS. Therefore, paraffin-embedded tumor material may be scarce at diagnosis but more plentiful at the time of definitive surgical local control. If our results are validated by other groups and in larger study cohorts, it may be feasible to evaluate tumor material from later in the disease course to infer expression at initial diagnosis.
The objective response rate of 10% to 15% for IGF-1R monoclonal antibodies in the treatment of patients with relapsed EWS motivates studies to understand possible resistance pathways to IGF-1R and other tyrosine kinase inhibitors. This experience also highlights the need to consider the potential for combining inhibitors of multiple different signaling pathways with each other and with conventional chemotherapy. [28] [29] [30] [31] Although IGF-1R, EGFR, and mTOR are all potential drug targets, it is yet to be fully determined if inhibition of any of these pathways can be augmented by simultaneously targeting other pathways. 32, 33 The ability to quantify pathway components and establish clinically relevant levels will be important to determine how the expression of these proteins drive tumor growth, survival, and drug sensitivity. Ultimately, finding the optimal targeted strategy for an individual patient may be informed by studies quantifying protein expression in that individual's tumor.
Prior studies have evaluated the clinical impact of some of these signaling proteins in EWS. The IGFBP-3:IGF-1 ratio has been correlated to younger age at time of diagnosis but this did not correlate to outcomes. 34 A separate study evaluating 45 paraffin-embedded samples showed higher standard IHC expression levels of p-mTOR, and p27(KIP1) were significantly associated with improved outcome. 20 These levels were not compared with the upstream drug targets evaluated in our study. A different report showed that patients whose tumors only showed nuclear staining of IGF-1R had better overall survival in a group of patients treated with an IGF-1R inhibitor. 25 The extent to which more quantitative approaches, such as AQUA, might improve upon the predictive ability of these markers remains to be established.
One limitation of our study was the pooling of data obtained from samples obtained before and after initiation of chemotherapy. The samples obtained after start of treatment are likely enriched with tumor cells that were not responsive to therapy and may have different biologic properties compared with those cells that were sensitive to chemotherapy. Data suggest that patients with poor chemotherapy induced necrosis, which are the specimens that likely had adequate posttreatment tumor samples, have worse overall outcomes. 35 Although our immunohistochemical assays assays for phospho-AKT and phospho-P70S were not successful, other studies have been able to do so using formalin-fixed paraffin-embedded tissue from other tumor types. 36, 37 This may be due either to biologic differences of the tumor type and/or differences in laboratory techniques. In addition, our sample size and retrospective study design make it difficult to determine the true correlation between quantitative methods of expression and standard IHC. Larger prospective studies are needed to clarify the optimal approach for each protein of interest.
On the basis of our findings, we conclude that growth signaling pathway proteins in EWS can be measured in a quantitative manner. The 3 assays evaluated have advantages and disadvantages that need to be considered in choosing an assay for a particular indication. Larger samples and a defined gold standard for comparison will be needed to determine the optimal approach for quantifying signaling proteins in EWS. These methods can then be used to aid the development of targeted therapies and evaluated as potential biomarkers predictive of response.
